A2DSYC Linde plc

DGAP-News: Lincare Statement Regarding COVID-19

DGAP-News: Linde plc / Key word(s): Miscellaneous
Lincare Statement Regarding COVID-19

25.03.2020 / 17:03
The issuer is solely responsible for the content of this announcement.


Lincare Statement Regarding COVID-19

Lincare, a subsidiary of Linde (NYSE:LIN; FWB:LIN), the leading provider of home respiratory care in the U.S., stands as a second line of defense in support of efforts to address the COVID-19 (coronavirus) public healthcare crisis. Throughout this pandemic, Lincare remains committed to:

- Ensuring continued care to 1.6 million patients across the U.S. supported by more than 2,000 Lincare clinicians.

- Providing in-home services to patients with underlying chronic medical conditions who may be more vulnerable when contracting COVID-19.

- Helping to increase critical hospital capacity by transitioning respiratory patients and
others from in-patient to in-home care.

Clearwater, FL - March 25, 2020 - Lincare, a subsidiary of Linde (NYSE:LIN; FWB:LIN) is playing a critical role in caring for patients at home, including some who have tested positive for COVID-19. The company is helping to ease the burden on hospitals across the country by partnering with them to transition patients who are eligible for in-home care, which results in additional hospital capacity for patients requiring critical care. Lincare patients who have tested positive for COVID-19 have received respiratory services including oxygen and nebulized respiratory medications, as well as ventilation services.

"Lincare is well-prepared to safely and reliably provide critical in-home services throughout the COVID-19 pandemic," said Lincare CEO Crispin Teufel. "As a leader in the homecare industry, Lincare is taking all necessary steps to play an active role in fighting this pandemic as a trusted provider for our patients. This includes adhering to industry standards and protocols to help ensure the safety of our patients and our employees. We stand with our fellow healthcare providers - doctors, nurses, caregivers, and clinical staff who are dedicated to providing an excellent standard of care to patients nationwide."

About Lincare

Lincare is the largest U.S. provider of respiratory care in the home with a broad geographic reach, offering an extensive portfolio of quality products and services: Respiratory Therapy, Sleep Therapy, INR Testing, Nebulizer and Respiratory Medications, Enteral Therapy, and Durable Medical Equipment. Lincare's mission is to set the standard for excellence, transforming the way respiratory care is delivered in the home. We are inspired by a vision to enable patients with chronic conditions to remain engaged in life, with the peace of mind that we are caring for them. Visit

Further information, email:

 

About Linde

Linde is a leading global industrial gases and engineering company with 2019 sales of $28 billion (€25 billion). We live our mission of making our world more productive every day by providing high-quality solutions, technologies and services which are making our customers more successful and helping to sustain and protect our planet.

The company serves a variety of end markets including aerospace, chemicals, food and beverage, electronics, energy, healthcare, manufacturing and primary metals. Linde's industrial gases are used in countless applications, from life-saving oxygen for hospitals to high-purity & specialty gases for electronics manufacturing, hydrogen for clean fuels and much more. Linde also delivers state-of-the-art gas processing solutions to support customer expansion, efficiency improvements and emissions reductions.

For more information about the company and its products and services, please visit



25.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Linde plc
The Priestley Centre, 10 Priestley Road
GU2 7XY Guildford
United Kingdom
Phone:
E-mail:
Internet:
ISIN: IE00BZ12WP82
WKN: A2DSYC
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Moscow, NYSE, Luxembourg Stock Exchange (Euro MTF)
EQS News ID: 1007169

 
End of News DGAP News Service

1007169  25.03.2020 

fncls.ssp?fn=show_t_gif&application_id=1007169&application_name=news&site_id=research_pool
EN
25/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Linde plc

Alfonso Mariategui
  • Alfonso Mariategui

AIR LIQUIDE / LINDE: A-GAS-AJANDO AL INVERSOR (ANÁLISIS BANCO SABADELL...

A-gas-ajando al inversor. Mantenemos SOBREPONDERAR en ambas. Aquellos que se compraron hace 5 años a los principales players del sector gasístico europeo (AI y LIN) y han “dejado” a las acciones hacer su trabajo se han visto agasajados con unas rentabilidades del +35% y +146% vs Euro STOXX 50 respectivamente. Esto es reflejo de las cualidades del sector (oligopolio, barreras de entrada, capacidad para traspasar e incrementar precios, resiliencia y visibilidad de crecimiento futuro), que vemos c...

Research Department
  • Research Department

INFORME DIARIO 22 NOVIEMBRE (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: COLONIAL, GRIFOLS, IMPUESTOS, SECTOR BANCARIO. EUROPA: AIR LIQUIDE, LINDE. Dudas en los mercados Jornada de menos a más tras los resultados de Nvidia en las bolsas europeas, que terminaron con subidas moderadas y con el Ibex recuperando los 11.600 puntos. Así, dentro del STOXX 600, Seguros y Energía lideraron las ganancias, frente a Telecos y Bienes de Consumo que terminaron con las mayores caídas. En la Eurozona la confianza del consumidor prelim...

Alfonso Mariategui
  • Alfonso Mariategui

LINDE: RDOS. 3T’24 Y CAMBIO DE P.O. A LA BAJA (ANÁLISIS BANCO SABADELL...

Rdos. 3T'24 vs 3T'23: Ventas: 8.356 M dólares (+2,5% vs +2,8% BS(e) y +2,8% consenso); EBIT ajustado: 2.477 M dólares (+7,4% vs +6,4% BS(e) y +5,2% consenso); BDI ajustado: 1.896 M dólares (+6,3% vs +5,8% BS(e) y +5,7% consenso); Rdos. 9meses'24 vs 9meses'23: Ventas: 24.723 M dólares (+0,7% vs +0,8% BS(e) y +0,8% consenso); EBIT ajustado: 7.240 M dólares (+6,5% vs +6,2% BS(e) y +5,8% consenso); BDI ajustado: 5.576 M dólares (+6,5% vs +6,3% BS(e) y +6,3% consenso).

Research Department
  • Research Department

INFORME DIARIO 29 0CTUBRE + RDOS. ESPAÑA Y EUROPA 3T’24. IDEAS DESTACA...

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: BANCO SANTANDER, ECOENER, FERROVIAL. EUROPA: ADIDAS, LINDE. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. El Ibex reconquista los 11.900 puntos La semana previa a las elecciones en EE.UU. cuando publicarán resultados las “7 magníficas” arran...

Alfonso Mariategui
  • Alfonso Mariategui

LINDE: RDOS. 2T’24 (ANÁLISIS BANCO SABADELL)

Rdos. 2T'24 vs 2T'23: Ventas: 8.267 M dólares (+0,7% vs +0,9% consenso); EBIT: 2.286 M dólares (+8,6% vs +18,4% consenso); Rdos. 1S'24 vs 1S'23: Ventas: 16.367 M dólares (-0,2% vs +8,5% consenso); EBIT: 4.492 M dólares (-0,1% vs +13,5% consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch